Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 391, Issue 11, pp 1295–1299 | Cite as

N-Ethylmaleimide differentiates between the M2- and M4-autoreceptor-mediated inhibition of acetylcholine release in the mouse brain

  • Justine Etscheid
  • Klaus Mohr
  • Eberhard Schlicker
Brief Communication
  • 92 Downloads

Abstract

Muscarinic M2 and M4 receptors resemble each other in brain distribution, function, and Gi/o protein signaling. However, there is evidence from human recombinant receptors that the M4 receptor also couples to Gs protein whereas such an alternative signaling is of minor importance for its M2 counterpart. The question arises whether this property is shared by native receptors, e.g., the murine hippocampal M2- and the striatal M4-autoreceptor. To this end, the electrically evoked tritium overflow was studied in mouse hippocampal and striatal slices pre-incubated with 3H-choline. 3H-Acetylcholine release in either region was inhibited by the potent muscarinic receptor agonist iperoxo (pIC50 8.6–8.8) in an atropine-sensitive manner (apparent pA2 8.6–8.8); iperoxo was much more potent than oxotremorine (pIC50 6.5–6.6). In hippocampal slices, N-ethylmaleimide (NEM) 32 μM, which inactivates Gi/o proteins, tended to shift the concentration-response curve of iperoxo (pIC50 8.8) to the right (pIC50 8.5) and depressed its maximum from 85 to 69%. In striatal slices, the inhibitory effect of iperoxo declined at concentrations higher than 0.1 μM, yielding a biphasic curve with a pIC50 of 8.6 for the falling part and a pEC50 of 6.4 for the rising part of the curve. The inhibitory effect of iperoxo 10 μM (47%) after NEM pre-treatment was lower by about 35% compared to the maximum (74%) obtained without NEM. In conclusion, our data, which need to be confirmed by pertussis toxin, might suggest that in the striatum, unlike the hippocampus, stimulatory Gs protein comes into play at high concentrations of a muscarinic receptor agonist.

Keywords

Acetylcholine release N-Ethylmaleimide Iperoxo M2 receptor M4 receptor 

Notes

Acknowledgements

The authors would like to thank the NRW International Graduate Research School Biotech-Pharma for a scholarship to J.E., Mrs. D. Petri † for her skilled technical assistance, and Prof. U. Holzgrabe for a gift of iperoxo.

Author contribution statement

KM and ES conceived and designed the research. JE conducted experiments. JE and ES analyzed the data. ES wrote the manuscript. All authors read and approved the manuscript.

Compliance with ethical standards

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrison NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, collaborators CGTP (2017) The concise guide to pharmacology 2017/18: G protein-coupled receptors. Br J Pharmacol 174:S17–S129CrossRefGoogle Scholar
  2. Allgaier C, Choi BK, Hertting G (1993) Muscarine receptors regulating electrically evoked release of acetylcholine in hippocampus are linked to pertussis toxin-sensitive G proteins but not to adenylate cyclase. J Neurochem 61:1043–1049CrossRefGoogle Scholar
  3. Bymaster FP, Calligaro DO, Falcone JF (1999) Arachidonic acid release in cell lines transfected with muscarinic receptors: a simple functional assay to determine response of agonists. Cell Signal 11:405–413CrossRefGoogle Scholar
  4. Caulfield MP, Birdsall NJ (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279–290PubMedGoogle Scholar
  5. Croy CH, Schober DA, Xiao H, Quets A, Christopoulos A, Felder CC (2014) Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M2 and M4 receptors. Mol Pharmacol 86:106–115CrossRefGoogle Scholar
  6. Dallanoce C, Conti P, De Amici M, De Micheli C, Barocelli E, Chiavarini M, Ballabeni V, Bertoni S, Impicciatore M (1999) Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorg Med Chem 7:1539–1547CrossRefGoogle Scholar
  7. Huang F, Buchwald P, Browne CE, Farag HH, Wu WM, Ji F, Hochhaus G, Bodor N (2001) Receptor binding studies of soft anticholinergic agents. AAPS Pharm Sci 3(4):E30CrossRefGoogle Scholar
  8. Jackisch R, Hotz H, Allgaier C, Hertting G (1994) Presynaptic opioid receptors on dopaminergic nerves in the rabbit caudate nucleus: coupling to pertussis toxin-sensitive G-proteins and interaction with D2 auto receptors? Naunyn Schmiedeberg’s Arch Pharmacol 349:250–258CrossRefGoogle Scholar
  9. Janßen N (2011) Zelluläre dynamische Massenumverteilung zur Erfassung der Signalwegsaktivierung 7-transmembranärer Rezeptoren unter besonderer Berücksichtigung des M4-Acetylcholinrezeptors. Dissertation, University of BonnGoogle Scholar
  10. Janßen N, Kebig A, Mohr K (2011) Differential sensitivity of the muscarinic M2 and M4 receptor for biased signaling in response to dualsteric agonists. Naunyn Schmiedeberg’s Arch Pharmacol 383(Suppl 1):54Google Scholar
  11. Lebois EP, Thorn C, Edgerton JR, Popiolek M, Xi S (2017) Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer’s disease. Neuropharmacology 136:362–373.  https://doi.org/10.1016/j.neuropharm.2017.11.018 CrossRefPubMedGoogle Scholar
  12. Michal P, El-Fakahany EE, Doležal V (2007) Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther 320:607–614CrossRefGoogle Scholar
  13. Richards MH (1990) Relative potencies of agonists and differential sensitivity to N-ethylmaleimide of muscarinic autoreceptors and postsynaptic receptors in rat hippocampus. J Pharmacol Exp Ther 255:83–89PubMedGoogle Scholar
  14. Schlicker E, Malinowska B, Kathmann M, Göthert M (1994) Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 8:128–137CrossRefGoogle Scholar
  15. Schulte K, Steingrüber N, Jergas B, Redmer A, Kurz CM, Buchalla R, Lutz B, Zimmer A, Schlicker E (2012) Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. Naunyn Schmiedeberg’s Arch Pharmacol 385:385–396CrossRefGoogle Scholar
  16. Scimeni A, Beato M (2009) Determining the neurotransmitter concentration profile at active synapses. Mol Neurobiol 40:289–306CrossRefGoogle Scholar
  17. Shinoda M, Katada T, Ui M (1990) Selective coupling of purified alpha-subunits of pertussis toxin-substrate GTP-binding proteins to endogenous receptors in rat brain membranes treated with N-ethylmaleimide. Cell Signal 2:403–414CrossRefGoogle Scholar
  18. Valuskova P, Farar V, Forczek S, Krizova I, Myslivecek J (2018) Autoradiography of 3H-pirenzepine and 3H-AFDX-384 in mouse brain regions: possible insights in M1, M2 and M4 muscarinic receptors distribution. Front Pharmacol 9:124CrossRefGoogle Scholar
  19. Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721–733CrossRefGoogle Scholar
  20. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J (2002) Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 22:1709–1717CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Justine Etscheid
    • 1
    • 2
  • Klaus Mohr
    • 1
  • Eberhard Schlicker
    • 2
  1. 1.Pharmacology and Toxicology Section, Institute of PharmacyUniversity of BonnBonnGermany
  2. 2.Institute of Pharmacology and ToxicologyUniversity of BonnSigmund-Freud-Str. 25, 53127 BonnGermany

Personalised recommendations